Azithromycin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pelvic Inflammatory Disease

Conditions

Pelvic Inflammatory Disease

Trial Timeline

May 1, 2009 → Nov 1, 2010

NCT ID

NCT00871494

About Azithromycin

Azithromycin is a phase 3 stage product being developed by Pfizer for Pelvic Inflammatory Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00871494. Target conditions include Pelvic Inflammatory Disease.

What happened to similar drugs?

3 of 5 similar drugs in Pelvic Inflammatory Disease were approved

Approved (3) Terminated (1) Active (2)

✅Solifenacin + PlaceboAstellas PharmaApproved

✅Conjugated Estrogens Cream + Placebo CreamPfizerApproved

✅Sevoflurane + propofol + remifentanilBaxterApproved

🔄Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)BayerPhase 3

🔄Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & MetronidazoleBayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002089	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002309	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002344	Phase 1	Completed	—	—	Bacterial Infections
NCT00002082	Pre-clinical	Completed	—	—	Cryptosporidiosis
NCT00002139	Phase 1	Completed	—	—	Bacterial Infections
NCT00002328	Pre-clinical	Completed	—	—	Cryptosporidiosis
NCT00002085	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002090	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT01919996	Phase 2	Terminated	Dec 1, 2013	Nov 1, 2015	Pharyngitis
NCT00871494	Phase 3	Completed	May 1, 2009	Nov 1, 2010	Pelvic Inflammatory Disease
NCT00809328	Phase 3	Completed	Feb 1, 2009	Mar 1, 2010	Community Acquired Pneumonia (CAP)
NCT00939185	Pre-clinical	Completed	Apr 1, 2007	Jan 1, 2009	Respiratory Tract Infections
NCT00229944	Phase 3	Completed	Dec 1, 2002	May 1, 2004	Cholera
NCT01227395	Pre-clinical	Completed	Jul 1, 2002	Mar 1, 2012	HIV Infection
NCT00599079	Approved	Completed	Feb 1, 1993	May 18, 2017	Mycobacterium Avium Complex Lung Disease

Competing Products

11 competing products in Pelvic Inflammatory Disease

See all competitors

Product	Company	Stage	Hype Score
Solifenacin + Placebo	Astellas Pharma	Approved	35
BGS649 + Placebo	Novartis	Phase 2	27
Tanezumab + Placebo	Pfizer	Phase 2	35
Vaginal estrogen + Placebo	Pfizer	Pre-clinical	18
Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet	Pfizer	Phase 2	27
Conjugated Estrogens Cream + Placebo Cream	Pfizer	Approved	43
BAY1834845 + Placebo	Bayer	Phase 1	26
Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)	Bayer	Phase 3	37
Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole	Bayer	Phase 3	37
Dienogest (BAY86-5258, Visanne)	Bayer	Pre-clinical	23
Sevoflurane + propofol + remifentanil	Baxter	Approved	40